Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058680863> ?p ?o ?g. }
- W2058680863 endingPage "1862" @default.
- W2058680863 startingPage "1851" @default.
- W2058680863 abstract "The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer.In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life.The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P<0.001 by the log-rank test for all comparisons). Hazard ratios for relapse (or death without relapse) (0.69; 95% confidence interval [CI], 0.58 to 0.82; P<0.001) and death from any cause (0.67; 95% CI, 0.55 to 0.82; P<0.001) favored epirubicin plus CMF over CMF alone. Independent prognostic factors were nodal status, tumor grade, tumor size, and estrogen-receptor status (P<0.001 for all four factors) and the presence or absence of vascular or lymphatic invasion (P=0.01). These factors did not significantly interact with the effect of epirubicin plus CMF. The overall incidence of adverse effects was significantly higher with epirubicin plus CMF than with CMF alone but did not significantly affect the delivered-dose intensity or the quality of life.Epirubicin plus CMF is superior to CMF alone as adjuvant treatment for early breast cancer. (ClinicalTrials.gov number, NCT00003577 [ClinicalTrials.gov].)." @default.
- W2058680863 created "2016-06-24" @default.
- W2058680863 creator A5000041911 @default.
- W2058680863 creator A5000187483 @default.
- W2058680863 creator A5012156686 @default.
- W2058680863 creator A5018398778 @default.
- W2058680863 creator A5019108235 @default.
- W2058680863 creator A5020490043 @default.
- W2058680863 creator A5023179046 @default.
- W2058680863 creator A5024501263 @default.
- W2058680863 creator A5026610840 @default.
- W2058680863 creator A5034389894 @default.
- W2058680863 creator A5038448622 @default.
- W2058680863 creator A5043287088 @default.
- W2058680863 creator A5043753160 @default.
- W2058680863 creator A5047823836 @default.
- W2058680863 creator A5050804752 @default.
- W2058680863 creator A5058248316 @default.
- W2058680863 creator A5060939857 @default.
- W2058680863 creator A5071542321 @default.
- W2058680863 creator A5082292420 @default.
- W2058680863 creator A5083306545 @default.
- W2058680863 creator A5091704063 @default.
- W2058680863 date "2006-11-02" @default.
- W2058680863 modified "2023-10-14" @default.
- W2058680863 title "Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer" @default.
- W2058680863 cites W1262485082 @default.
- W2058680863 cites W1723350107 @default.
- W2058680863 cites W1815937178 @default.
- W2058680863 cites W1848007259 @default.
- W2058680863 cites W1848579801 @default.
- W2058680863 cites W1863343593 @default.
- W2058680863 cites W1882532563 @default.
- W2058680863 cites W1891831617 @default.
- W2058680863 cites W1900639705 @default.
- W2058680863 cites W2029934161 @default.
- W2058680863 cites W2043512623 @default.
- W2058680863 cites W206480088 @default.
- W2058680863 cites W2104337757 @default.
- W2058680863 cites W2122140751 @default.
- W2058680863 cites W2123851087 @default.
- W2058680863 cites W2124924898 @default.
- W2058680863 cites W2125396123 @default.
- W2058680863 cites W2137583404 @default.
- W2058680863 cites W2138602439 @default.
- W2058680863 cites W2138839431 @default.
- W2058680863 cites W2149708286 @default.
- W2058680863 cites W2149908785 @default.
- W2058680863 cites W2154097160 @default.
- W2058680863 cites W2167571044 @default.
- W2058680863 cites W2243148137 @default.
- W2058680863 cites W2338983050 @default.
- W2058680863 cites W3041047318 @default.
- W2058680863 cites W4229734735 @default.
- W2058680863 cites W4234837271 @default.
- W2058680863 doi "https://doi.org/10.1056/nejmoa052084" @default.
- W2058680863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17079759" @default.
- W2058680863 hasPublicationYear "2006" @default.
- W2058680863 type Work @default.
- W2058680863 sameAs 2058680863 @default.
- W2058680863 citedByCount "179" @default.
- W2058680863 countsByYear W20586808632012 @default.
- W2058680863 countsByYear W20586808632013 @default.
- W2058680863 countsByYear W20586808632014 @default.
- W2058680863 countsByYear W20586808632015 @default.
- W2058680863 countsByYear W20586808632016 @default.
- W2058680863 countsByYear W20586808632017 @default.
- W2058680863 countsByYear W20586808632018 @default.
- W2058680863 countsByYear W20586808632019 @default.
- W2058680863 countsByYear W20586808632020 @default.
- W2058680863 countsByYear W20586808632021 @default.
- W2058680863 countsByYear W20586808632022 @default.
- W2058680863 countsByYear W20586808632023 @default.
- W2058680863 crossrefType "journal-article" @default.
- W2058680863 hasAuthorship W2058680863A5000041911 @default.
- W2058680863 hasAuthorship W2058680863A5000187483 @default.
- W2058680863 hasAuthorship W2058680863A5012156686 @default.
- W2058680863 hasAuthorship W2058680863A5018398778 @default.
- W2058680863 hasAuthorship W2058680863A5019108235 @default.
- W2058680863 hasAuthorship W2058680863A5020490043 @default.
- W2058680863 hasAuthorship W2058680863A5023179046 @default.
- W2058680863 hasAuthorship W2058680863A5024501263 @default.
- W2058680863 hasAuthorship W2058680863A5026610840 @default.
- W2058680863 hasAuthorship W2058680863A5034389894 @default.
- W2058680863 hasAuthorship W2058680863A5038448622 @default.
- W2058680863 hasAuthorship W2058680863A5043287088 @default.
- W2058680863 hasAuthorship W2058680863A5043753160 @default.
- W2058680863 hasAuthorship W2058680863A5047823836 @default.
- W2058680863 hasAuthorship W2058680863A5050804752 @default.
- W2058680863 hasAuthorship W2058680863A5058248316 @default.
- W2058680863 hasAuthorship W2058680863A5060939857 @default.
- W2058680863 hasAuthorship W2058680863A5071542321 @default.
- W2058680863 hasAuthorship W2058680863A5082292420 @default.
- W2058680863 hasAuthorship W2058680863A5083306545 @default.
- W2058680863 hasAuthorship W2058680863A5091704063 @default.
- W2058680863 hasBestOaLocation W20586808631 @default.
- W2058680863 hasConcept C121608353 @default.
- W2058680863 hasConcept C126322002 @default.